Highlights
- Up to 61% of US adults (approximately 148 million) meet FDA-approved indications for at least one novel CKM therapy (GLP-1RA, SGLT2i, or nsMRA).
- Over 11.7 million US adults are currently eligible for ‘triple therapy’ combining all three classes, highlighting a massive implementation frontier.
- Adherence to a healthy lifestyle combined with GLP-1RA therapy reduces MACE risk by 43%, significantly outperforming either intervention alone.
- New evidence suggests semaglutide and liraglutide are associated with a lower risk of worsening mental illness, offering a dually effective option for comorbid depression and diabetes.
Background
The conceptualization of Cardiovascular-Kidney-Metabolic (CKM) syndrome reflects the clinical reality that obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular disease (CVD) are not isolated entities but a pathological continuum. In recent years, the therapeutic landscape has been transformed by three major drug classes: glucagon-like peptide 1 receptor agonists (GLP-1RAs), sodium-glucose cotransporter-2 inhibitors (SGLT2is), and nonsteroidal mineralocorticoid receptor antagonists (nsMRAs). While their clinical efficacy is well-documented in randomized controlled trials (RCTs), the actual population-level eligibility across different healthcare settings—and the potential for multi-organ protection—remains a critical area of investigation for health policy and clinical practice.
Key Content
Population-Level Eligibility and the Implementation Gap
A pivotal cross-sectional analysis by Mounsey et al. (2026) utilized data from the National Health and Nutrition Examination Survey (NHANES), pooled community cohorts, and large ambulatory healthcare systems (BIDMC and MGB) to quantify medication eligibility. The findings are staggering: 60% of the US adult population (148 million individuals) qualify for at least one CKM medication under current FDA-approved indications.
Eligibility for GLP-1RAs was the most prevalent, encompassing 56% of adults in the NHANES sample (137.1 million people). SGLT2i eligibility followed at 24% (57.9 million), while nsMRA eligibility stood at 5% (11.7 million). Interestingly, the study noted a discrepancy between survey-based data and ambulatory healthcare samples; eligibility in clinic settings (BIDMC 42%, MGB 46%) was lower than in the general population survey (60%). This suggests either a healthier ‘worried well’ population visiting these specific systems or, more likely, a significant under-documentation of the clinical markers (such as BMI or albuminuria) required to trigger these indications.
The Synergy of Lifestyle and Pharmacotherapy
A prospective cohort study from the US Veterans Affairs’ Million Veteran Program (PMID: 41763234) provided robust evidence for the integration of GLP-1RAs with low-risk lifestyle habits. Analyzing 98,261 participants, researchers found that while GLP-1RAs alone reduced major adverse cardiovascular events (MACE) by 16% (HR 0.84), the combination of these drugs with six to eight healthy lifestyle factors (including diet, sleep, and physical activity) resulted in a 43% reduction in MACE risk (HR 0.57). This underscores that the ‘magic bullet’ of pharmacotherapy does not replace the foundation of lifestyle modification but rather acts synergistically with it.
Neuropsychiatric Implications of CKM Therapies
One of the most provocative shifts in CKM management is the potential for neuropsychiatric benefit. A Swedish national cohort study (PMID: 41862258) examined the risk of worsening mental illness in over 95,000 individuals with depression or anxiety. Semaglutide was associated with a significantly lower risk of worsening mental illness (aHR 0.58), including reductions in depression, anxiety, and substance use disorder. This within-individual analysis suggests that the metabolic stabilization provided by GLP-1RAs may have direct or indirect neuroprotective effects, potentially alleviating the high burden of psychiatric comorbidities in patients with CKM syndrome (PMID: 41730813).
Social Determinants and Disease Severity
The rise in clinical obesity—a primary driver of CKM eligibility—is not uniform across the population. Analysis of NHANES data from 1999 to 2023 (PMID: 41734890) reveals that the prevalence of clinical obesity has nearly doubled (14.3% to 26.6%). Crucially, disparities are widening; individuals with high cumulative social determinants of health (SDOH) burden, such as food insecurity and unemployment, are significantly more likely to present with Class II or III obesity. This suggests that expanding medication eligibility must be paired with public health interventions addressing structural inequities.
Advances in Precision CKM Management
Beyond the ‘Big Three’ medication classes, precision medicine is encroaching on CKM-related endocrine disorders. The GRACE trial (PMID: 41730814) demonstrated that Relacorilant, a selective glucocorticoid receptor modulator, significantly improved hypertension control in patients with Cushing’s syndrome—a condition often presenting with severe CKM phenotype. Similarly, the use of genetic markers (USP8 status) in Cushing’s disease (PMID: 41785910) highlights a trend toward biomarker-driven risk stratification in metabolic care.
Expert Commentary
The data from Mounsey et al. and related studies present a dual reality: we possess powerful tools to combat the CKM epidemic, yet the scale of eligibility is so vast that it threatens to overwhelm current delivery models. The finding that 11.7 million Americans qualify for triple therapy (GLP-1RA + SGLT2i + nsMRA) is particularly noteworthy. While the clinical benefits of such combinations are mechanically sound—targeting glucose regulation, sodium handling, and mineralocorticoid-mediated fibrosis simultaneously—the financial and logistical burden of such regimens is significant.
Furthermore, the ‘psychiatric-metabolic’ link highlighted in the PsyMetRiC 2.0 study (PMID: 41831468) and the Swedish GLP-1RA study suggests that CKM care must move out of the ‘cardio-renal’ silo. Clinicians should view GLP-1RAs as potentially beneficial for mental health stability in diabetic patients, while psychiatrists must become more adept at monitoring metabolic risk in young patients with psychosis who are at high risk for early MACE.
One major controversy remains the ‘preclinical’ versus ‘clinical’ obesity threshold. As we see a 20.6% prevalence of preclinical obesity (adiposity without complications), the question of whether to initiate therapy earlier to prevent the progression to overt CKM syndrome remains a subject of intense debate among policy experts and payers.
Conclusion
The management of CKM syndrome has entered a new era where majority eligibility for advanced pharmacotherapy is the norm rather than the exception. With up to 148 million US adults qualifying for treatment, the focus must shift from identifying ‘who’ is eligible to ‘how’ we deliver these therapies equitably and sustainably. Future research must prioritize the long-term outcomes of triple therapy and the integration of digital health tools (such as the PsyMetRiC app or automated insulin delivery systems) to manage the cognitive and therapeutic burden on patients. Ultimately, the successful mitigation of the CKM crisis will require a multi-pronged approach combining precision pharmacotherapy, rigorous lifestyle support, and a dedicated focus on social determinants of health.
References
- Mounsey LA, et al. Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples. JAMA Cardiol. 2026;11(3):250-258. PMID: 41604173.
- Swedish National Cohort Study. Association between GLP-1 receptor agonist use and worsening mental illness. Lancet Psychiatry. 2026;13(4):327-335. PMID: 41862258.
- Veterans Affairs Million Veteran Program. Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes. Lancet Diabetes Endocrinol. 2026;14(4):317-326. PMID: 41763234.
- RADIANT Trial. Tubeless automated insulin delivery versus multiple daily injections in type 1 diabetes. Lancet Diabetes Endocrinol. 2026;14(4):305-316. PMID: 41747751.
- GRACE Trial. Efficacy and safety of relacorilant for the treatment of patients with Cushing’s syndrome. Lancet Diabetes Endocrinol. 2026;14(4):291-304. PMID: 41730814.
- NHANES Trend Analysis. Trends in the Prevalence of Clinical and Preclinical Obesity Among US Adults. Obesity (Silver Spring). 2026;34(4):939-951. PMID: 41734890.
